DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy ; volume:10 ; number:1 ; day:27 ; month:5 ; year:2024 ; pages:1-14 ; date:12.2024
Cell death discovery ; 10, Heft 1 (27.5.2024), 1-14, 12.2024
- Urheber
-
Choi, Seong Hee
Mani, Muralidharan
Kim, Jeonghwan
Cho, Wha Ja
Martin, Thomas F. J.
Kim, Jee Hyun
Chu, Hun Su
Jeong, Won Jin
Won, Young-Wook
Lee, Byung Ju
Ahn, Byungyong
Kim, Junil
Jeon, Do Yong
Park, Jeong Woo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-024-02027-x
- URN
-
urn:nbn:de:101:1-2408060903487.142901443918
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Choi, Seong Hee
- Mani, Muralidharan
- Kim, Jeonghwan
- Cho, Wha Ja
- Martin, Thomas F. J.
- Kim, Jee Hyun
- Chu, Hun Su
- Jeong, Won Jin
- Won, Young-Wook
- Lee, Byung Ju
- Ahn, Byungyong
- Kim, Junil
- Jeon, Do Yong
- Park, Jeong Woo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway